This Plain Language Summary from Immunotherapy summarises a study called POETYK PSO-1. The study looked at a new treatment called deucravacitinib for a skin condition called plaque psoriasis.

Read the full article here.

This is a summary of a paper published in a medical journal that describes the results of a study called POETYK PSO-1, which looked at a new treatment called deucravacitinib for plaque psoriasis. Plaque psoriasis appears on the body as round or oval raised patches (called plaques) typically covered by scales. This can cause the skin to itch, crack or bleed, and the associated itching and pain can make it difficult to perform basic everyday tasks. Living with psoriasis can cause emotional distress. Treatments are available, but some do not always reduce the symptoms of psoriasis, some may need to be injected or taken multiple times a day, and some may have side effects. Researchers are looking for new treatments that are more effective, convenient to take, and have acceptable safety and tolerability.

Play the video below to see the author giving an overview of the PLSP.


The original article which this summary is based on is called ‘Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase 3 POETYK PSO-1 trial’, published in the Journal of the American Academy of Dermatology. Read the original article here.